Mind Medicine MindMed Inc. diskutieren
Mind Medicine MindMed Inc.
WKN: A3DR6E / Symbol: MNMD / Name: Mind Medicine MindMed / Aktie / Small Cap /
5,07 €
2,38 %
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $21.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $5.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at EF Hutton Acquisition Co. I. They now have a $21.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $22.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target raised by analysts at Royal Bank of Canada from $5.00 to $7.00. They now have an "outperform" rating on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $7.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is now covered by analysts at Canaccord Genuity Group Inc.. They set a "buy" rating and a $9.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target raised by analysts at Royal Bank of Canada from $14.00 to $15.00. They now have an "outperform" rating on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $75.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is now covered by analysts at SVB Leerink LLC. They set an "outperform" rating and a $20.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "outperform" rating re-affirmed by analysts at Leerink Partnrs.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its price target lowered by analysts at HC Wainwright from $75.00 to $35.00. They now have a "buy" rating on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $20.00 price target on the stock, down previously from $29.00.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $35.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is now covered by analysts at Robert W. Baird. They set an "outperform" rating and a $27.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "outperform" rating re-affirmed by analysts at Royal Bank of Canada. They now have a $22.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is now covered by analysts at Roth Mkm. They set a "buy" rating and a $36.00 price target on the stock.
Ratings data for MNMD provided by MarketBeat
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) was upgraded by analysts at Roth Capital to a "strong-buy" rating.
Ratings data for MNMD provided by MarketBeat
Neueste Beiträge
StockNews_com in Ampio Pharmaceuticals Inc. diskutieren